eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
5/2006
vol. 10
 
Share:
Share:
abstract:

Effectiveness and toxicity of Interleukin 2, Interferon α,and 5-Fluorouracil in patients with Metastatic Renal Cell Cancer

Jerzy Tujakowski
,
Krzysztof Roszkowski
,
Rodryg Ramlau
,
Bogdan Żurawski

Współcz Onkol 2006; 5: 231-235
Online publish date: 2006/06/26
View full text Get citation
 

Purpose:
The purpose of this study was
to evaluate the potential efficacy and
toxicity for the treatment of metastatic
renal cell cancer.

Material and methods:
During the first
4 weeks of treatment, patients received
s.c. IL-2 (Proleukin) in weeks 1 and 4
(10 MIU/m2 once daily on days 3-5), in
weeks 2 and 3 (5 MIU/m2 once daily on
days 3-5). During weeks 2 and 3, the
dosage for IFN-2B (Roferon) was 5 MIU/m2
on days 1, 3 and 5, in weeks 5-8
(10 MIU/m2 once daily on days 1, 3 and 5.
During weeks 5-8, 5-Fu (5 Fluorouracyl)
1000 mg/m2 was administered once
weekly by a bolus i.v. injection. Eighteen
patients entered the study. All had
undergone a nephrectomy and had
progressive metastatic disease.

Results:
There were one patient with
complete responses (CRs) and three with
partial responses (PRs) for an objective
response rate of 22.2% (95% confidence
interval). The CR durations were
20 months for one patient. The patient
who remains disease-free had the
disease in the lung and kidney. The PR
durations ranged from 2 to 9 months. The
median survival of the study group is 8.7
months (range 1 to 23 months). The most
common toxicities during IL-2/IFN and
5-Fu were fatigue, nausea/vomiting,
anorexia, skin rash, injection site
inflammation, diarrhea, fever. 12 of 18
patients experienced grade 2/3
granulocytopenia, and four other patients
experienced thrombocytopenia. An
out-patient treatment system was feasible
and positively viewed by the patients.

Conclusions:
In view of a lack of effective
therapy methods, the immunochemotherapy
applied by the authors on all
metastatic renal cell carcinoma patients,
may be an optional treatment, with an
acceptable level of complications.
keywords:

immunochemotherapy, metastatic renal cell cancer, IL-2, IFN, 5-Fu

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.